A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Phase 3

Started

2026-08-17

Last updated

2026-09-04

Condition(s) studied

Atopic Dermatitis

Investigational drug(s) / intervention(s)

Tilrekimig →Placebo

Tilrekimig: Subcutaneous Injections at required timepoints

Placebo: Subcutaneous Injections at required timepoints

Study summary

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated.

* This study is seeking participants who: Are aged 12 years or older.
* Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.

Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20.

Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.

Eligibility

Sex

ALL

Min age

12 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants 12 years of age or older * Must meet the following AD criteria: 1. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1 2. An inadequate response to standard of care treatments {eg, at least medium potency topical corticosteroids (TCS)} consistent with AD treatment guidelines 3. Moderate-to-severe eczema for at least 1 year * Adolescent participants must be up to date on immunizations per local guidance. Exclusion Criteria: * Clinically Significant Autoimmune Disease * Significant Infection History or Active Infection * Known or Suspected Immunodeficiency/Immunosuppression * Significant psychiatric illness or suicidality * Clinically significant hepatic, renal, or hematologic abnormalities

Primary outcome measure(s)

Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placebo — Week 16
Difference in the proportion of Validated Investigator Global Assessment (vIGA)-AD™ 0/1 responders between tilrekimig versus placebo — Week 16

Trial sites (3)

Facility	City	Region	Status
Northridge Clinical Trials	Northridge	California	Not Yet Recruiting
AllerVie Clinical Research	Panama City	Florida	Not Yet Recruiting
GCP Research , Global Clinical Professionals	St. Petersburg	Florida	Recruiting

More Pfizer trials in the USA

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Active, not recruiting

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy Active, not recruiting

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Recruiting

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania Active, not recruiting

Other trials for the same condition

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults Recruiting

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis Active, not recruiting

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis Recruiting

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07765888 on ClinicalTrials.gov ↗ ← All trials in the USA